AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01202825
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.
Trial: NCT01202825
Drug: TMC647055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
Trial: NCT01202825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
Trial: NCT01202825
Drug: TMC647055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
Trial: NCT01988571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet taken each morning orally for 24 months.
Trial: NCT01964911
Drug: Ropivacaïne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN \<3/10 : non opioids, EN 3-5/10 : weak opioids, EN\>5/10 : strong opioids).~If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.~In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days).
Trial: NCT02187302
Drug: CRLX101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02187302
Drug: Standard of Care (Investigator Choice)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00638703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00143611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
Trial: NCT04358497
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NSAID treatment
Trial: NCT03746522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection of placebo
Trial: NCT00323414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
Trial: NCT00606892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar Pill
Trial: NCT00606892
Drug: IV Nic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
Trial: NCT00804336
Drug: SOM230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
Trial: NCT00804336
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally once a day
Trial: NCT03240627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cutaneous solution
Trial: NCT03862391
Drug: Analgesics
RxNorm normalized name: ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: while patients are in the PACU after general anesthesia, if patients' VAS scores are higher than 3, we will give them 50 mg of deksketoprofen as analgesic.
Trial: NCT03862391
Drug: Antiemetics
RxNorm normalized name: ANTIEMETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: while patients are in the PACU after general anesthesia, if patient' Nausea and vomiting scores are higher than 1, we will give them 4 mg of ondansetron
Trial: NCT00648219
Drug: Benicar® Tablets 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg, single dose fed
Trial: NCT00515827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg placebo tablet taken orally twice daily
Trial: NCT02327923
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inj fentanyl 1.5mg/kg will be given at the time of induction.
Trial: NCT02327923
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02442778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as capsules.
Trial: NCT02442778
Drug: AVP-786-42.63
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 42.63 mg of d6-DM and 4.9 mg of Q
Trial: NCT01248299
Drug: FU-CDDP
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 21 days:~* Fluoro-uracil \[800 mg/m2, day 1 to day 5\]~* CisPlatin \[75 mg/m2, day 1 or day 2\]
Trial: NCT01248299
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 14 days:~* Oxaliplatin \[85 mg/m2 by 2h infusion, day 1\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, by 22h continous infusion, day 1 and day 2\]~* Elvorin \[500 mg/m2, day 1 and day 2\]
Trial: NCT01248299
Drug: TPF
RxNorm normalized name: Docetaxel, Cisplatin, and Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 21 days:~* Docetaxel \[30 mg/m2, day 1 and day 8\]~* CisPlatin \[60 mg/m2, day 1\]~* Fluoro-uracil \[200 mg/m2/day by continous infusion\]~Or every 21 days:~* Docetaxel \[50 mg/m2, day 1\]~* CisPlatine \[70 mg/m2, day 1\]~* Fluoro-uracile \[700 mg/m2 /day, day 1 to day 5\]
Trial: NCT02264002
Drug: Cilobradine low dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02264002
Drug: Cilobradine medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02264002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02213211
Drug: Artemether lumefantrine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02643654
Drug: MABp1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
Trial: NCT02643654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
Trial: NCT00605046
Drug: SPECT scan
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV151-01: Evaluation of \[123I\] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
Trial: NCT02296814
Drug: Sinusitis Hevert SL Tablet
RxNorm normalized name: sinusitisinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
Trial: NCT02296814
Drug: Placebo for Sinusitis Hevert SL Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
Trial: NCT01387204
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
Trial: NCT01247090
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
Trial: NCT01891851
Drug: TMC435350 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
Trial: NCT02076412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet PO bid (morning and evening)
Trial: NCT03814954
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
Trial: NCT02484703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
Trial: NCT02484703
Drug: RO5186582
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
Trial: NCT00262067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo consisted of the vehicle for bevacizumab without the antibody.
Trial: NCT00262067
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~1. Docetaxel 75-100 mg/m\^2 IV~2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle
Trial: NCT03829046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 weeks of treatment
Trial: NCT01547416
Drug: no epidural drug administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg.
Trial: NCT01638962
Drug: Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)
RxNorm normalized name: acetaminophen / diphenhydramine Oral Tablet [Unisom with Pain Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.
Trial: NCT00858871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
Trial: NCT00858871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
Trial: NCT03736850
Drug: CS3006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s).
Trial: NCT02617550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 14 +/-3 days given as 1 or 2 tablets \[o.d.\].
Trial: NCT03346122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Trial: NCT01589432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo capsules
Trial: NCT00095758
Drug: Antidepressant + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Trial: NCT00758628
Drug: Bromefenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac BID 3 months
Trial: NCT01660412
Drug: Standard of Care First
RxNorm normalized name: Standard ANSI First Aid KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40.
Trial: NCT04063033
Drug: IV iron - Sodium Ferric Gluconate Complex
RxNorm normalized name: sodium ferric gluconate complex
DrugBank: Sodium ferric gluconate complex (DB09517)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
Trial: NCT00665600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo TID
Trial: NCT03551210
Drug: Placebo (250 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl (250 ml), solution for infusion
Trial: NCT03551210
Drug: Placebo (100 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl (100 ml), solution for infusion
Trial: NCT03108248
Drug: ethiodized oil; doxorubicin;Gelfoam;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.
Trial: NCT00095797
Drug: R(+)XK469
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00947297
Drug: HPN-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
Trial: NCT00003217
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003217
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003217
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002510
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03132051
Drug: steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
Trial: NCT04380857
Drug: Topical Prednisolone Acetate Ophthalmic Drops
RxNorm normalized name: prednisolone acetate Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Prednisolone acetate ophthalmic drops per standard of care:~Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue
Trial: NCT00514267
Drug: YM 155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00973791
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
Trial: NCT04734405
Drug: Prof-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prof-001 cream
Trial: NCT01888497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, prior to bedtime on the night before performance testing
Trial: NCT00983554
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testim 10g daily
Trial: NCT04734405
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ointment base to mimic Prof-001
Trial: NCT04734405
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: encapsulated lactose powder to mimic 150 mg fluconazole capsule
Trial: NCT01610596
Drug: Halobetasol Propionate Lotion 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
Trial: NCT01610596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01388829
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
Trial: NCT01388829
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
Trial: NCT00202904
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
Trial: NCT00864162
Drug: Atlace® 10 mg capsules, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
Trial: NCT01276314
Drug: anti- TNF-a
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg BIW, SC
Trial: NCT01276314
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-1.5 mg / kg / day
Trial: NCT03202004
Drug: GSK2894512 1% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 % (10 mg/g) GSK2894512 cream will be provided in tubes labeled in compliance with country requirements.
Trial: NCT03202004
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream will be provided in tubes labeled in compliance with country requirements.
Trial: NCT02677090
Drug: Dose 1 - Promitor®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02677090
Drug: Dose 2 - Promitor®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02677090
Drug: Dose 3 - Promitor®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00514410
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
Trial: NCT00514410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo taken once a day for three months
Trial: NCT00952094
Drug: KRN1493
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
Trial: NCT00028756
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00028756
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03613207
Drug: Oraqix® gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
Trial: NCT01034410
Drug: AS1411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS1411 40mg/kg/day or AS1411 80mg/kg/day
Trial: NCT00808288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, inhaled, dry powder, placebo, OD
Trial: NCT01870128
Drug: Combination Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
Trial: NCT01870128
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 15 to 25 mg PO per week
Trial: NCT01870128
Drug: Combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
Trial: NCT00080847
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00080847
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV